Panitumumab–FOLFOX4 Treatment and RAS Mutations in Colorectal Cancer
Open accessThe DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Patients with metastatic colorectal cancer that harbors KRAS mutations in exon 2 do not benefit from anti-epidermal growth factor receptor (EGFR) therapy. Other activating RAS mutations may also be negative predictive biomarkers for anti-EGFR therapy. METHODS: In this prospective-retrospective analysis, we assessed the efficacy and safety of panitumumab plus oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) as compared with FOLFOX4 alone, according to RAS (KRAS or NRAS) or BRAF mutation status. A total of 639 patients who had metastatic colorectal cancer without KRAS mutations in exon 2 had results for at least one of the following: KRAS exon 3 or 4; NRAS exon 2, 3, or 4; or BRAF exon 15. The overall rate of ascertainment of RAS status was 90%. RESULTS: Among 512 patients without RAS mutations, progression-free survival was 10.1 months with panitumumab-FOLFOX4 versus 7.9 months with FOLFOX4 alone (hazard ratio for progression or death with combination therapy, 0.72; 95% confidence interval [CI], 0.58 to 0.90; P=0.004). Overall survival was 26.0 months in the panitumumab-FOLFOX4 group versus 20.2 months in the FOLFOX4-alone group (hazard ratio for death, 0.78; 95% CI, 0.62 to 0.99; P=0.04). A total of 108 patients (17%) with nonmutated KRAS exon 2 had other RAS mutations. These mutations were associated with inferior progression-free survival and overall survival with panitumumab-FOLFOX4 treatment, which was consistent with the findings in patients with KRAS mutations in exon 2. BRAF mutations were a negative prognostic factor. No new safety signals were identified. CONCLUSIONS: Additional RAS mutations predicted a lack of response in patients who received panitumumab-FOLFOX4. In patients who had metastatic colorectal cancer without RAS mutations, improvements in overall survival were observed with panitumumab-FOLFOX4 therapy. (Funded by Amgen and others; PRIME ClinicalTrials.gov number, NCT00364013.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Consistent with BRAFV600E mutation, signaling independent of upstream input, anti-EGFR therapy is not useful in patients with BRAFV600E tumors as single agents [93] or in combination with chemotherapy [94].”
From Recent Advances in Therapeutic Strategies to Improve Colorectal Cancer Treatment (2024) · cites this paper as [94]
In the citing paper
“Additional rare mutations of KRAS, as well as mutations of NRAS, have been associated with primary resistance to treatment.”
From Primary and acquired resistance to EGFR-targeted therapies in colorectal cancer: impact on future treatment strategies (2014) · cites this paper as [35]
In the citing paper
“Further analysis of molecular subgroups in this study showed that adding panitumumab significantly improved mPFS and mOS in the non-mutated KRAS group but was ineffective in patients with KRAS non-exon 2 mutations [15].”
From RAS Mutations in Advanced Colorectal Cancer: Mechanisms, Clinical Implications, and Novel Therapeutic Approaches (2025) · cites this paper as [15]
In the citing paper
“Genetic analysis has shown that 98% of RAS mutations that cause cancer are concentrated in three residues: G12, G13, and Q61.”
From The Role of KRAS Mutations in Colorectal Cancer: Biological Insights, Clinical Implications, and Future Therapeutic Perspectives (2025) · cites this paper as [18]
In the citing paper
“The most frequently detected mutations in codons 12 and 13—namely G12V (incidence: 20–25%), G12S (5–7%), G12R (3–5%), G12A (3–5%), and G13D (15–20%)—are also clinically relevant, with their prevalence varying by tumor type [16,17,18].”
From The Role of KRAS Mutations in Colorectal Cancer: Biological Insights, Clinical Implications, and Future Therapeutic Perspectives (2025) · cites this paper as [18]
3 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Toxicity and response criteria of the Eastern Cooperative Oncology Group
Oken, M. M., Creech, R. H., Tormey, D. C., Horton, J., Davis, T. E., McFadden, E. T., & Carbone, P. P. (1982) · AMERICAN JOURNAL OF CLINICAL ONCOLOGY · doi:10.1097/00000421-198212000-00014 · Cited by 11,647
Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer
Van Cutsem, E., Köhne, C.-H., Hitre, E., Zaluski, J., Chang Chien, C.-R., Makhson, A., D'Haens, G., Pintér, T., Lim, R., Bodoky, G., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0805019 · Cited by 3,877 · cited 5×
“Worst grade of 5 14 (5) 16 (6) 30 (6) 19 (7) 10 (4) 29 (5)”
InfluentialSelf-citationWild-Type KRAS Is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer
Amado, R. G., Wolf, M., Peeters, M., Van Cutsem, E., Siena, S., Freeman, D. J., Juan, T., Sikorski, R., Suggs, S., Radinsky, R., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.7116 · Cited by 3,207 · cited 4×
“Not determined 4/320 (1) 8/321 (2) 12/641 (2)”
InfluentialSelf-citationCOSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer
Forbes, S. A., Bindal, N., Bamford, S., Cole, C., Kok, C. Y., Beare, D., Jia, M., Shepherd, R., Leung, K., Menzies, A., et al. (2011) · Nucleic Acids Research · doi:10.1093/nar/gkq929 · Cited by 2,278 · cited 3×
“Not serious 48 (19) 28 (11) 76 (15) 50 (19) 24 (9) 74 (14)”
De Roock, W., Claes, B., Bernasconi, D., De Schutter, J., Biesmans, B., Fountzilas, G., Kalogeras, K. T., Kotoula, V., Papamichael, D., Laurent-Puig, P., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70130-3 · Cited by 2,144 · cited 1×
“Not serious 48 (19) 28 (11) 76 (15) 50 (19) 24 (9) 74 (14)”
Self-citationVan Cutsem, E., Köhne, C.-H., Láng, I., Folprecht, G., Nowacki, M. P., Cascinu, S., Shchepotin, I., Maurel, J., Cunningham, D., Tejpar, S., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.33.5091 · Cited by 1,882
Self-citationDouillard, J.-Y., Siena, S., Cassidy, J., Tabernero, J., Burkes, R., Barugel, M., Humblet, Y., Bodoky, G., Cunningham, D., Jassem, J., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.4860 · Cited by 1,809 · cited 2×
“Not determined 4/320 (1) 8/321 (2) 12/641 (2)”
Self-citationWild-Type BRAF Is Required for Response to Panitumumab or Cetuximab in Metastatic Colorectal Cancer
Di Nicolantonio, F., Martini, M., Molinari, F., Sartore-Bianchi, A., Arena, S., Saletti, P., De Dosso, S., Mazzucchelli, L., Frattini, M., Siena, S., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.0786 · Cited by 1,591
Self-citationRas oncogenes: split personalities
Karnoub, A. E., & Weinberg, R. A. (2008) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2438 · Cited by 1,467 · cited 3×
“Worst grade of 5 14 (5) 16 (6) 30 (6) 19 (7) 10 (4) 29 (5)”
Peeters, M., Price, T. J., Cervantes, A., Sobrero, A. F., Ducreux, M., Hotko, Y., André, T., Chan, E., Lordick, F., Punt, C. J. A., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.6055 · Cited by 1,005
Self-citation
Research works printed but not linked: 2
- Wojcik P, 2008, Pol J Pathol, 59, 93
- Yuen ST, 2002, Cancer Res, 62, 6451
Cited by
Items 501–600 of 1,008
Development of a Novel c-MET–Based CTC Detection Platform
Zhang, T., Boominathan, R., Foulk, B., Rao, C., Kemeny, G., Strickler, J. H., Abbruzzese, J. L., Harrison, M. R., Hsu, D. S., Healy, P. N., et al. (2016) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-16-0011 · Cited by 44
“Other than RASmutations in colorectal cancer (26, 27) and HER2 expression in gastric cancer (28–30), there are few validated predictive biomarkers that are clinically useful in patients with metastatic prostate, renal cell, bladder, colorectal, gastric, and pancreatic cancers (26).”
BackgroundZheng, G., Lin, M., Lokhandwala, P. M., Beierl, K. F., Netto, G. J., Gocke, C. D., Eshleman, J. R., McCarthy, E. F., & Illei, P. B. (2016) · Cancer Cytopathology · doi:10.1002/cncy.21743 · Cited by 41
“protein kinase kinase (MEK) inhibitor trametinib, and selecting patients with colorectal cancer who have neither KRAS nor neuroblastoma v-Ras oncogene homolog (NRAS) mutations for treatment with anti-EGFR monoclonal antibodies (cetuximab and panitumumab).(9,10) Adequate tissue sampling and optimal processing are criti…”
BackgroundMiR-384 inhibits human colorectal cancer metastasis by targeting KRAS and CDC42
Wang, Y., Chen, Y., Liu, S., Ye, Y., Jiao, H., Wang, S., Xiao, Z., Wei, W., Qiu, J., Li, L., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.12704 · Cited by 41
“The molecular alterations such as RAS or BRAF mutations in CRC patients affect the clinical therapeutic effects [10, 11].”
BackgroundSilva, V. S. E., Chinen, L. T. D., Abdallah, E. A., Damascena, A. S., Paludo, J., Chojniak, R., Dettino, A. L. A., de Mello, C. A. L., Alves, V. S., & Fanelli, M. F. (2016) · OncoTargets and Therapy · doi:10.2147/ott.s115268 · Cited by 42
Role of Biologics in First-Line Treatment of Colorectal Cancer
Mahipal, A., & Grothey, A. (2016) · Journal of Oncology Practice · doi:10.1200/jop.2016.018382 · Cited by 39
Bachet, J., Moreno-Lopez, N., Viganò, L., Marchèse, U., Gelli, M., Raoux, L., Truant, S., Laurent, C., Herrero, A., Roy, B. L., et al. (2019) · British journal of surgery · doi:10.1002/bjs.11180 · Cited by 41
Jiao, H., Weng, B.-S., Yan, S.-S., Lin, Z., Wang, S., Chen, X.-P., Liang, G.-H., Li, X., Zhao, W., Huang, J.-Y., et al. (2020) · Cell Death and Disease · doi:10.1038/s41419-020-02793-3 · Cited by 46
RetractedFerreira, C. G., Aran, V., Zalcberg-Renault, I., Victorino, A. P., Salem, J. H., Bonamino, M., Vieira, F. M. D. A. C., & Zalis, M. G. (2014) · BMC Gastroenterology · doi:10.1186/1471-230x-14-73 · Cited by 44
“have analysed the importance of codon 61 (less frequently found mutated in CRC) [18], at the time we started our study mutational analysis of KRAS codons 12 and 13 was standard for patients with mCRC.”
BackgroundRankin, A., Klempner, S. J., Erlich, R., Sun, J. X., Grothey, A., Fakih, M., George, T. J., Lee, J., Ross, J. S., Stephens, P. J., et al. (2016) · The Oncologist · doi:10.1634/theoncologist.2016-0148 · Cited by 40
The role of ischaemia-reperfusion injury and liver regeneration in hepatic tumour recurrence
Maspero, M., Yılmaz, S., Cazzaniga, B., Raj, R., Ali, K., Mazzaferro, V., & Schlegel, A. A. (2023) · JHEP Reports · doi:10.1016/j.jhepr.2023.100846 · Cited by 53
“Cetuximab and panitumumab are anti-EGFR monoclonal antibodies used in metastatic CRC either in combination with chemotherapy or as monotherapy.(122,123) HGF is a major driver of hepatocyte proliferation during liver regeneration.”
BackgroundState-of-the-Art Management of Colorectal Cancer: Treatment Advances and Innovation
Pathak, P., Chan, G. H. J., Deming, D. A., & Chee, C. E. (2024) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_438466 · Cited by 49
Hamid, M. A., Pammer, L. M., Oberparleiter, S., Günther, M., Amann, A., Gruber, R., Mair, A., Nocera, F. I., Ormanns, S., Zimmer, K., et al. (2025) · npj Precision Oncology · doi:10.1038/s41698-025-00892-y · Cited by 49
Amatu, A., Barault, L., Moutinho, C., Cassingena, A., Bencardino, K. B., Ghezzi, S., Palmeri, L., Bonazzina, E. F., Tosi, F., Ricotta, R., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw071 · Cited by 40
Self-citationYao, J., Zang, W., Ge, Y., Weygant, N., Yu, P., Li, L., Rao, G., Jiang, Z., Yan, R., He, L., et al. (2018) · Canadian Journal of Gastroenterology and Hepatology · doi:10.1155/2018/4248971 · Cited by 44
“Our ctDNA results are in line with previous studies which also demonstrated that RAS/BRAF mutant patients are associated with reduced efficacy of first-line therapy [5].”
ResultSundar, R., Miranda, S., Rodrigues, D. N., Chénard-Poirier, M., Dolling, D. I., Clarke, M., Figueiredo, I., Bertan, C. M., Yuan, W., Ferreira, A., et al. (2018) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2018.05.011 · Cited by 41
Self-citationMTORC1/2 Inhibition as a Therapeutic Strategy for PIK3CA Mutant Cancers
Fricke, S. L., Payne, S. N., Favreau, P. F., Kratz, J. D., Pasch, C. A., Foley, T. M., Yueh, A. E., Van De Hey, D. R., Depke, M. G., Korkos, D. P., et al. (2019) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-18-0510 · Cited by 41
“In 2009, KRAS exon 2 testing became the standard of care as a marker of resistance to the anti-epidermal growth factor receptor (EGFR) therapies, cetuximab and panitumumab (3-5).”
BackgroundIchida, H., Mise, Y., Ito, H., Ishizawa, T., Inoue, Y., Takahashi, Y., Shinozaki, E., Yamaguchi, K., & Saiura, A. (2019) · World Journal of Surgical Oncology · doi:10.1186/s12957-019-1641-5 · Cited by 40
Johnson, B., Loree, J. M., Jacome, A. A. D. A., Mendis, S. R., Syed, M., Morris, V. K., Parseghian, C. M., Dasari, A. N., Pant, S., Raymond, V. M., et al. (2019) · JCO Precision Oncology · doi:10.1200/po.19.00102 · Cited by 44
“Although BRAF mCRC is known to be predictive of poor response to anti-EGFR therapy, the clinical utility of EGFR inhibition in aBRAF mCRC remains unclear.(4,5) Of note, previous retrospective work investigating a cohort of 150 patients with refractory mCRC identified seven patients with aBRAF mutations and reported po…”
ResultBeyond RAS and BRAF: HER2, a New Actionable Oncotarget in Advanced Colorectal Cancer
Guarini, C., Grassi, T., Pezzicoli, G., & Porta, C. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22136813 · Cited by 44
“KRAS wild-type) [19,20] play a key (and growing) role.”
BackgroundSun, L., Huang, S., Li, D., Ye, M., Wang, Y., & Wu, J. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.754881 · Cited by 41
Duffy, M. J., & Crown, J. P. (2022) · Journal of Personalized Medicine · doi:10.3390/jpm12010099 · Cited by 42
Roberts, T. J., Kehl, K. L., Brooks, G. A., Sholl, L. M., Wright, A. A., Landrum, M. B., & Keating, N. L. (2023) · JAMA Network Open · doi:10.1001/jamanetworkopen.2023.10809 · Cited by 43
Reverse Phase Protein Arrays: Mapping the Path Towards Personalized Medicine
Gallagher, R. I., & Espina, V. A. (2014) · Molecular Diagnosis & Therapy · doi:10.1007/s40291-014-0122-3 · Cited by 40
“For example, epidermal growth factor receptor (EGFR) is a validated therapeutic target in colon cancer [18, 19].”
Price, T. J., Bruhn, M. A., Lee, C. K., Hardingham, J. E., Townsend, A. R., Mann, K. P., Simes, J., Weickhardt, A., Wrin, J. W., Wilson, K., et al. (2015) · British Journal of Cancer · doi:10.1038/bjc.2015.37 · Cited by 39
“(Douillard et al, 2013; Heinemann et al, 2014; Schwartzberg et al, 2014).”
BackgroundSelf-citationKriegsmann, M., Arens, N., Endris, V., Weichert, W., & Kriegsmann, J. (2015) · Diagnostic Pathology · doi:10.1186/s13000-015-0364-3 · Cited by 43
“Downstream signalling of EGFR activates RAS- and RAF-genes that are members of this pathway and can harbour oncogenic mutations in 30–60 % (KRAS) [3–6], 5–20 % (BRAF) [7–9] and 1–3 % (NRAS) [10, 11] of cases respectively.”
BackgroundResultInfluentialCurrent and Future Therapies for Advanced Gastric Cancer
Davidson, M., Okines, A. F. C., & Starling, N. (2015) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2015.05.013 · Cited by 51
Targeted Therapy in Older Patients With Solid Tumors
Kelly, C. M., Power, D. G., & Lichtman, S. M. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.55.4246 · Cited by 41
Dvorak, K., Higgins, A., Palting, J. D., Cohen, M. J., & Brunhoeber, P. (2017) · Pathology & Oncology Research · doi:10.1007/s12253-017-0344-x · Cited by 42
Peeters, M., Price, T. J., Taïeb, J., Geißler, M., Rivera, F., Canon, J.-L. R., Pentheroudakis, G. E., Koukakis, R., Burdon, P., & Siena, S. (2018) · British Journal of Cancer · doi:10.1038/s41416-018-0165-z · Cited by 42
Self-citationPeeters, M., Price, T. J., Boedigheimer, M. J., Kim, T. W., Ruff, P., Gibbs, P., Thomas, A., Demonty, G., Hool, K., & Ang, A. L. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-2072 · Cited by 40
“Activating RASmutations have been shown to predict a lack of response to anti-EGFR therapy and are associated with inferior outcomes in patients withmCRC (11).”
BackgroundSelf-citationGutierrez, M. E., Price, K. S., Lanman, R. B., Nagy, R. J., Shah, I., Mathura, S., Mulcahy, M., Norden, A. D., & Goldberg, S. L. (2019) · JCO Precision Oncology · doi:10.1200/po.19.00274 · Cited by 46
“KRAS exon 2 mutation testing allows oncologists to avoid the use of ineffective anti-EGFR therapy in approximately 40% of patients with mCRC who may otherwise receive these drugs as second-line therapy.(3) Over the subsequent 10 years, biomarker testing guidelines have been expanded (Fig 1).”
BackgroundRaghav, K. P. S., Ou, F., Venook, A. P., Innocenti, F., Sun, R., Lenz, H., & Kopetz, S. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.22.00365 · Cited by 42
“INTRODUCTION Antiepidermal growth factor receptor antibodies (anti– EGFR-Abs), panitumumab and cetuximab, are highly effective against RAS/BRAF wild-type (WT) metastatic colorectal cancer (mCRC).(1,2) Barring patients who have intrinsic or primary resistance to EGFR inhibition, a substantial proportion will derive ini…”
BackgroundBerry, W., Algar, E. M., Kumar, B., Desmond, C., Swan, M. P., Jenkins, B. J., & Croagh, D. G. (2017) · International Journal of Cancer · doi:10.1002/ijc.30648 · Cited by 41
“Another novel aspect of our current study was the use of TCGA to characterize the most prevalent treatable cancer phenotype, KRAS wild-type tumours, in PC, and thus build on previous studies demonstrating that KRAS wild-type acts as a biomarker for anti-EGFR treatment in colorectal and lung cancers [13, 26-29].”
ResultDienstmann, R., Salazar, R., & Tabernero, J. (2014) · American Society of Clinical Oncology Educational Book · doi:10.14694/edbook_am.2014.34.91 · Cited by 38
Self-citationNew structural and functional insight into the regulation of Ras
Kano, Y., Cook, J. D., Lee, J. E., & Ohh, M. (2016) · Seminars in Cell & Developmental Biology · doi:10.1016/j.semcdb.2016.06.006 · Cited by 38
“EGFR antibody (Cetuximab and Panitumumab) showed a high response rate even in advanced colon cancer patients[22,23].”
BackgroundThe Fundamental Difficulty With Evaluating the Accuracy of Biomarkers for Guiding Treatment
Janes, H., PEPE, M. S., McShane, L. M., Sargent, D. J., & Heagerty, P. J. (2015) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djv157 · Cited by 40
Cetuximab-Induced MET Activation Acts as a Novel Resistance Mechanism in Colon Cancer Cells
Song, N., Liu, S., Zhang, J., Liu, J., Xu, L., Liu, Y., & Qu, X. (2014) · International Journal of Molecular Sciences · doi:10.3390/ijms15045838 · Cited by 37
“Recently, NRAS mutations have emerged as an indicator for EGFR-targeted agent [3].”
BackgroundFrom Genotype to Functional Phenotype: Unraveling the Metabolomic Features of Colorectal Cancer
Bathe, O. F., & Farshidfar, F. (2014) · Genes · doi:10.3390/genes5030536 · Cited by 43
“NRAS mutations are resistant to EGFR inhibitors [111,112].”
BackgroundClinicopathological characteristics and prognostic impact of colorectal cancers with NRAS mutations
Ogura, T., Kakuta, M., Yatsuoka, T., Nishimura, Y., Sakamoto, H., Yamaguchi, K., Tanabe, M., Tanaka, Y., & Akagi, K. (2014) · Oncology Reports · doi:10.3892/or.2014.3165 · Cited by 41
“Recent studies suggest that other activating mutations in KRAS or NRAS, in addition to KRAS exon 2, confer resistance to anti-EGFR therapy (9,11,13,21).”
BackgroundRAS Mutations as Predictive Biomarkers in Clinical Management of Metastatic Colorectal Cancer
Waring, P. M., Tie, J., Maru, D. M., & Karapetis, C. S. (2015) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2015.10.006 · Cited by 45
Li, W., Qiu, T., Guo, L., & Ying, J. (2017) · Cancer Letters · doi:10.1016/j.canlet.2017.09.014 · Cited by 45
An Update on Colorectal Cancer
Xue, L., Williamson, A. J., Gaines, S., Andolfi, C., Paul-Olson, T., Neerukonda, A. R., Steinhagen, E. F., Smith, R. K., Cannon, L. M., Polite, B. N., et al. (2018) · Current Problems in Surgery · doi:10.1067/j.cpsurg.2018.02.003 · Cited by 42
Marín, J. J. G., Macías, R. I. R., Monte, M. J., Herráez, E., Peleteiro‐Vigil, A., de Blas, B. S., Sanchon-Sanchez, P., Temprano, Á. G., Espinosa-Escudero, R. A., Lozano, E., et al. (2020) · Cancers · doi:10.3390/cancers12092605 · Cited by 44
Sadeghlar, F., Vogt, A., Mohr, R. U., Mahn, R., van Beekum, K., Kornek, M., Weismüller, T. J., Branchi, V., Matthaei, H., Toma, M. I., et al. (2020) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-020-02746-x · Cited by 38
BRAF-induced tumorigenesis is IKKα-dependent but NF-κB–independent
Margalef, P., Colomer, C., Villanueva, A., Montagut, C. O., Iglesias, M., Bellosillo, B., Salazar, R., Martínez‐Iniesta, M., Bigas, A., & Espinosa, L. (2015) · Science Signaling · doi:10.1126/scisignal.2005886 · Cited by 39
“Clinically relevant RAS mutations are difficult to target and preclude the use of EGFR inhibitors such as cetuximab or panitumumab in advanced metastatic CRC (1-3).”
BackgroundCurrent and Future Trends of Colorectal Cancer Treatment: Exploring Advances in Immunotherapy
Nikolouzakis, T. K., Chrysos, E., Docea, A. O., Fragkiadaki, P., Souglakos, J., Tsiaoussis, J., & Tsatsakis, A. (2024) · Cancers · doi:10.3390/cancers16111995 · Cited by 37
“The authors assumed that the observed difference in OS can be explained by the fact that shorter telomeres may be associated with increased non-tumor-related mortality.”
BackgroundGraham, C. N., Hechmati, G., Hjelmgren, J., Liège, F. D., Lanier, J., Knox, H. N., & Barber, B. (2014) · European Journal of Cancer · doi:10.1016/j.ejca.2014.08.016 · Cited by 40
Kjersem, J. B., Skovlund, E., Ikdahl, T., Guren, T. K., Kersten, C., Dalsgaard, A. M., Yilmaz, M., Fokstuen, T., Tveit, K. M., & Kure, E. H. (2014) · BMC Cancer · doi:10.1186/1471-2407-14-340 · Cited by 38
Does bevacizumab impact anti-EGFR therapy efficacy in metastatic colorectal cancer?
Dérangère, V., Fumet, J.-D., Boidot, R., Bengrine-Lefèvre, L., Limagne, E., Chevriaux, A., Vincent, J., Ladoire, S., Apétoh, L., Rébé, C., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.7008 · Cited by 38
How should clinicians address intratumour heterogeneity in clear cell renal cell carcinoma?
Soultati, A. S., Stares, M., Swanton, C., Larkin, J., & Turajlic, S. (2015) · Current Opinion in Urology · doi:10.1097/mou.0000000000000204 · Cited by 40
“This is in contrast to other malignancies whereby response to therapy (BRAF-mutant melanoma/BRAF inhibitors [9]), primary resistance (RASmutant colorectal cancer/EGFR inhibitors [10]) and acquired resistance (MET amplification/ EGFR-”
ResultLiquid Biopsy: Approaches to Dynamic Genotyping in Cancer
von Bubnoff, N. C. C. (2017) · Oncology Research and Treatment · doi:10.1159/000478864 · Cited by 40
Madi, A., Fisher, D. J., Maughan, T., Colley, J. P., Meade, A. M., Maynard, J. H., Humphreys, V., Wasan, H. S., Adams, R., Idziaszczyk, S., et al. (2018) · European Journal of Cancer · doi:10.1016/j.ejca.2018.07.009 · Cited by 42
“receptor (EGFR) signalling pathway predict a lack of response to anti-EGFR mononclonal antibodies [1,2].”
BackgroundClifford, R. E., Govindarajah, N., Parsons, J. L., Gollins, S., West, N. P., & Vimalachandran, D. (2018) · British journal of surgery · doi:10.1002/bjs.10993 · Cited by 39
Kasi, P. M., & Grothey, A. F. (2016) · The Cancer Journal · doi:10.1097/ppo.0000000000000195 · Cited by 41
Arjona‐Sánchez, Á., Rodríguez‐Ortiz, L., Baratti, D., Schneider, M. A., Calvo, A. G., García-Fadrique, A., Tuynman, J. B., Cascales-Campos, P. A., Martín, V. C., Morales, R., et al. (2019) · Annals of Surgical Oncology · doi:10.1245/s10434-019-07378-9 · Cited by 38
Bekaii-Saab, T. S., Lach, K., Hsu, L.-I., Siadak, M., Stecher, M., Ward, J., Beckerman, R., & Strickler, J. H. (2023) · The Oncologist · doi:10.1093/oncolo/oyad200 · Cited by 36
Tack, V., Schuuring, E. M. D., Keppens, C., Hart, N. A. ‘., Pauwels, P., van Krieken, J. H., & Dequeker, E. M. C. (2018) · British Journal of Cancer · doi:10.1038/s41416-018-0204-9 · Cited by 38
Prognostic significance of K-Ras mutation rate in metastatic colorectal cancer patients
Vincenzi, B., Cremolini, C., Sartore-Bianchi, A., Russo, A., Mannavola, F., Perrone, G., Pantano, F., Loupakis, F., Rossini, D., Ongaro, E., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.5231 · Cited by 36
Self-citationColorectal cancer in Chinese patients: current and emerging treatment options
Ma, B. B. Y., & Li, L. (2014) · OncoTargets and Therapy · doi:10.2147/ott.s48409 · Cited by 36
“For example, treating RAS-mutant tumor patients with panitumumab may even have a detrimental effect on survival as shown in the Panitumumab Randomized Trial in Combination With Chemotherapy for Metastatic CRC to Determine Efficacy (PRIME) study, where patients were randomized to first-line chemotherapy with or without…”
MethodProgress Against GI Cancer During the American Society of Clinical Oncology's First 50 Years
Mayer, R. J., Venook, A. P., & Schilsky, R. L. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.55.4121 · Cited by 40
“The analysis of multiple clinical trial data sets has demonstrated that these drugs are not effective in colorectal tumors that harbor mutations in KRAS and NRAS genes (and likely the BRAF gene) and may even result in inferior outcomes when administered to patients whose tumors have such mutations.(128,129) Thus, test…”
Stahler, A., Heinemann, V., Giessen‐Jung, C., Crispin, A., Schalhorn, A., Stintzing, S., von Weikersthal, L. F., Vehling‐Kaiser, U., Stauch, M. B., Quietzsch, D., et al. (2015) · International Journal of Cancer · doi:10.1002/ijc.29807 · Cited by 38
“Consecutively, RAS (KRAS/NRAS exon 2-4) wild-type status is required for using EGFRtargeted agents in metastatic colorectal cancer (mCRC) since 2013.(5,6)”
MethodMichl, M., Stintzing, S., von Weikersthal, L. F., Decker, T. W., Kiani, A., Vehling-Kaiser, U., Al-Batran, S.-E., Heintges, T., Lerchenmueller, C., Kahl, C., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw222 · Cited by 36
“As today extended RAS mutational status replaces KRAS in view of anti-EGFR treatment efficacy [10-12], CEA analysis was performed in KRAS wild-type as well as in the extended RAS wild-type patients.”
BackgroundSolassol, J., Vendrell, J. A., Märkl, B., Haas, C., Bellosillo, B., Montagut, C. O., Smith, M. R., O’Sullivan, B., D’Haene, N., Mercier, M. L., et al. (2016) · PLoS ONE · doi:10.1371/journal.pone.0163444 · Cited by 39
Recent Advances in Chemotherapy and Surgery for Colorectal Liver Metastases
Passot, G., Soubrane, O., Giuliante, F., Zimmitti, G., Goèré, D., Yamashita, S., & Vauthey, J. (2016) · Liver Cancer · doi:10.1159/000449349 · Cited by 36
Loree, J. M., Kopetz, S., & Raghav, K. P. S. (2017) · Journal of Gastrointestinal Oncology · doi:10.21037/jgo.2017.01.01 · Cited by 38
Hseu, Y., Chao, Y.-H., Lin, K., Way, T., Lin, H., Thiyagarajan, V., & Yang, H. (2017) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2017.07.001 · Cited by 38
Belli, V., Matrone, N., Napolitano, S., Migliardi, G., Cottino, F., Bertotti, A., Trusolino, L., Martinelli, E., Morgillo, F., Ciardiello, D., et al. (2019) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-019-1230-z · Cited by 37
Galvano, A., Taverna, S., Badalamenti, G., Incorvaia, L., Castiglia, M., Barraco, N., Passiglia, F., Fulfaro, F., Beretta, G. D., Duro, G., et al. (2019) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835919874653 · Cited by 41
Maitland, M. L., Wilkerson, J., Karovic, S., Zhao, B., Flynn, J. R., Zhou, M., Hilden, P. D., Ahmed, F. S., Dercle, L., Moskowitz, C. S., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-1493 · Cited by 36
“For example, a follow-up analysis of available tissue from the trial revealed approximately 17% of patients in this “WT” cohort to have tumors bearing other-site KRAS, BRAF, or NRAS mutations which caused a similar degree of primary resistance to panitumumab as the codon 12/13 KRAS mutations (44).”
BackgroundMicroRNA-Based Therapeutics for Drug-Resistant Colorectal Cancer
Jung, E., Choi, J., Kim, J.-S., & Han, T. (2021) · Pharmaceuticals · doi:10.3390/ph14020136 · Cited by 37
“Using Nanostring nCounter-based analysis, researchers have confirmed the expression signatures of ERBB2, MLPH, IRX3, MYRF, and KLK6 in patients with panitumumab resistance [83,84].”
MethodYin, H., Li, W., Mo, L., Deng, S., Lin, W., Ma, C., Luo, Z., Luo, C., & Hong, H. (2021) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.16349 · Cited by 39
Osumi, H., Vecchione, L., Keilholz, U., Vollbrecht, C., Alig, A. H. S., von Einem, J. C., Stahler, A., Striefler, J. K., Kurreck, A., Kind, A. J., et al. (2021) · European Journal of Cancer · doi:10.1016/j.ejca.2021.05.010 · Cited by 39
Current concepts of anti-EGFR targeting in metastatic colorectal cancer
Doleschal, B., Petzer, A., & Rumpold, H. F. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.1048166 · Cited by 40
“PRIME further evaluated the possible negative predictive value of additional isoforms and exons of RAS and clearly showed that any activating mutation in KRAS or NRAS predicted resistance to Panitumumab (32).”
BackgroundJia, L.-L., Zhao, J.-X., Zhao, L., Tian, J., & Huang, G. (2022) · European Journal of Radiology · doi:10.1016/j.ejrad.2022.110640 · Cited by 42
Clinical management of regorafenib in the treatment of patients with advanced colorectal cancer
Sastre, J., Argilés, G., Benavides, M., Feliú, J., Alfonso, P. G., García‐Carbonero, R., Grávalos, C., Guillén‐Ponce, C., Martinez-Villacampa, M. M., & Pericay, C. (2014) · Clinical & Translational Oncology · doi:10.1007/s12094-014-1212-8 · Cited by 39
“7 %), FOLFOX4 (9 %), FOLFOX4 plus panitumumab (18 %) and cetuximab plus irinotecan (21 %) [17–19].”
Shankaran, V., Ortendahl, J. D., Purdum, A., Bolinder, B., Anene, A. M., Sun, G. H., & Bentley, T. G. K. (2015) · American Journal of Clinical Oncology · doi:10.1097/coc.0000000000000231 · Cited by 40
Boleij, A., Tack, V., Taylor, A., Kafatos, G., Jenkins-Anderson, S., Tembuyser, L., Dequeker, E., & van Krieken, J. H. (2016) · BMC Cancer · doi:10.1186/s12885-016-2810-3 · Cited by 38
“Key findings included efficacy analyses of first-line anti-EGFR therapy, in combination with chemotherapy, by RAS mutation status, which demonstrated that additional RAS mutations (other than KRAS exon 2) were predictive biomarkers for non-response to treatment [10].”
BackgroundNordlinger, B., Poston, G. J., & Goldberg, R. M. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.58.3989 · Cited by 37
Atreya, C. E., Yaeger, R., & Chu, E. (2017) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_175679 · Cited by 35
Understanding drug resistance in breast cancer: Mechanisms and emerging therapeutic strategies
Gautam, S., Maurya, R., Vikal, A., Patel, P., Thakur, S., Singh, A., Gupta, G. D., & Kurmi, B. D. (2025) · Medicine in Drug Discovery · doi:10.1016/j.medidd.2025.100210 · Cited by 44
RAS mutations and cetuximab in locally advanced rectal cancer: Results of the EXPERT-C trial
Sclafani, F., de Castro, D. G., Cunningham, D., Wilson, S. H., Peckitt, C., Giralt, J., Glimelius, B. L. G., Roselló, S., Wotherspoon, A. C., Brown, G. M., et al. (2014) · European Journal of Cancer · doi:10.1016/j.ejca.2014.02.002 · Cited by 38
Self-citationMusella, V., Pietrantonio, F., Buduo, E. D., Iacovelli, R., Martinetti, A., Sottotetti, E., Bossi, I. E., Maggi, C., Bartolomeo, M. D., de Braud, F., et al. (2015) · International Journal of Cancer · doi:10.1002/ijc.29493 · Cited by 35
“Alternative therapies should be prescribed when RAS mutations are detected, since such mutations were validated as predictive biomarkers of resistance to anti-EGFR treatment.(8,9) However, a significant percentage of patients not expressing any of the “negative” predictive Figure 3.”
BackgroundJesinghaus, M., Pfarr, N., Endris, V., Kloor, M., Volckmar, A., Brandt, R., Herpel, E., Muckenhuber, A., Lasitschka, F., Schirmacher, P., et al. (2016) · Genes Chromosomes and Cancer · doi:10.1002/gcc.22352 · Cited by 38
“As described previously (Pfarr et al., 2015a,b) bidirectional Sanger sequencing of all PCR products was subsequently conducted on an ABI 3130 Genetic Analyzer (Thermo Fisher Scientific, Waltham, USA) using the BigDye Terminator v1.”
BackgroundMethodInfluentialOuchi, K., Takahashi, S. I., Yamada, Y., Tsuji, S., Tatsuno, K., Takahashi, H., Takahashi, N., Takahashi, M., Shimodaira, H., Aburatani, H., et al. (2015) · Cancer Science · doi:10.1111/cas.12827 · Cited by 36
Picard, A., Pédeutour, F., Peyrade, F., Saudes, L., Duranton‐Tanneur, V., Chamorey, E., Cardot‐Leccia, N., Sudaka, A., Ettaiche, M., Benchetrit, M., et al. (2017) · JAMA Dermatology · doi:10.1001/jamadermatol.2017.0270 · Cited by 41
The management of colorectal liver metastases
Maher, B., Ryan, E., Little, M. W., Boardman, P., & Stedman, B. (2017) · Clinical Radiology · doi:10.1016/j.crad.2017.05.016 · Cited by 40
Battaglin, F., Puccini, A., Djaballah, S. A., & Lenz, H. (2019) · Cancer Management and Research · doi:10.2147/cmar.s186042 · Cited by 37
“02).(18) The presence of a BRAF mutation was also confirmed as an independent negative prognostic factor both for PFS and OS, irrespective of treatment.”
BackgroundGoel, S., Ocean, A. J., Parakrama, R. Y., Ghalib, M. H., Chaudhary, I., Shah, U., Viswanathan, S., Kharkwal, H., Coffey, M. C., & Maitra, R. (2020) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-19-1117 · Cited by 36
“Over the past decade, an oncogenic mutation in KRAS in a patient's tumor with mCRC is entrenched as a biomarker of exclusion of antiEGFR therapy (3, 27).”
Sumransub, N., Vantanasiri, K., Prakash, A., & Lou, E. (2021) · Molecular Therapy — Oncolytics · doi:10.1016/j.omto.2021.05.001 · Cited by 36
Molnar, B. A., Galamb, O., Kalmár, A., Barták, B. K., Nagy, Z. B., Tóth, K., Tulassay, Z., Igaz, P., & Dank, M. (2019) · Expert Review of Molecular Diagnostics · doi:10.1080/14737159.2019.1613891 · Cited by 37
Krikelis, D., Skoura, E. V., Kotoula, V., Rondogianni, P., Pianou, N. K., Samartzis, A. P., Xanthakis, I., Fountzilas, G., & Datseris, I. (2014) · PubMed · Cited by 37
KRAS mutation in lung metastases from colorectal cancer: prognostic implications
Ghidini, M., Personeni, N., Bozzarelli, S., Baretti, M., Basso, G., Bianchi, P. P., Tronconi, M. C., Pressiani, T., Grizzi, F., Giordano, L., et al. (2015) · Cancer Medicine · doi:10.1002/cam4.592 · Cited by 44
Chemotherapy in locally advanced head and neck squamous cell carcinoma
Gyawali, B., Shimokata, T., Honda, K., & Ando, Y. (2016) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2016.01.002 · Cited by 35
“As a reminder, panitumumab and cetuximab are not interchangeable in the management of LAHNSCC unlike colorectal cancer where both are equally effective [46,47].”
BackgroundSEOM clinical guidelines for diagnosis and treatment of metastatic colorectal cancer 2015
Aranda, E., Aparicio, J., Alonso, V., García‐Albéniz, X., Alfonso, P. G., Salazar, R., Valladares, M., Vera, R., Viéitez, J. M., & García‐Carbonero, R. (2015) · Clinical & Translational Oncology · doi:10.1007/s12094-015-1434-4 · Cited by 40
“In the RAS expanded analysis, PFS and OS were more favorable for the combination group [32].”
BackgroundNavarro-Jiménez, M., González, B., Mulet-Margalef, N., Hierro, C., & Alonso, S. (2025) · npj Precision Oncology · doi:10.1038/s41698-025-01166-3 · Cited by 44
“Conversely, other studies have shown that tumors with a KRAS A146 mutation are associated with resistance to anti-EGFR therapy 59,62 .”
Segelov, E., Chan, D. L. H., Shapiro, J. D., Price, T. J., Karapetis, C. S., Tebbutt, N. C., & Pavlakis, N. (2014) · British Journal of Cancer · doi:10.1038/bjc.2014.404 · Cited by 40
“…examination of exon 2 to include mutational hotspots in exons 3 and 4, as well as the NRAS gene (exons 2, 3 and 4) and (in some series) PI3KCA exon 20, has been established from the analysis of several first-line EGFR-I trials: PRIME (Douillard et al, 2013) and FIRE-3 (Stintzing et al, 2012).”
The potential role of immunotherapy to treat colorectal cancer
Amin, M. A., & Lockhart, A. C. (2014) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2015.985376 · Cited by 35
“It has shown improved PFS when compared to best supportive care [157,158].”
BackgroundThe role of targeted therapy for gastrointestinal tumors
Rolfo, C. D., Bronte, G., Sortino, G., Papadimitriou, K., Passiglia, F., Fiorentino, E., Marogy, G., Russo, A. D., & Peeters, M. (2014) · Expert Review of Gastroenterology & Hepatology · doi:10.1586/17474124.2014.922870 · Cited by 36
“In fact for RAS wild-type patients, the benefit in OS was observed for both these two combinations: FOLFIRI + cetuximab, as shown in the CRYSTAL trial [23] and FOLFOX + panitumumab, as reported in the PRIME trial after the specific evaluation of both KRAS and NRAS gene mutations [24].”
MethodThomsen, C. B., Hansen, T. F., Andersen, R. F., Lindebjerg, J., Jensen, L. H., & Jakobsen, A. K. M. (2018) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-018-0723-5 · Cited by 36
“We investigated the 26 most frequent KRAS and NRAS mutations in CRC and the most frequent RAF mutation, BRAF V600E, as further described in the supplementary material (Additional file 3: Table S2) [13, 14].”
BackgroundResultInfluentialLocked Nucleic Acid Technology for Highly Sensitive Detection of Somatic Mutations in Cancer
Ishige, T., Itoga, S., & Matsushita, K. (2017) · Advances in clinical chemistry · doi:10.1016/bs.acc.2017.10.002 · Cited by 39
Metadata
- Authors
- Douillard, J.-Y., Oliner, K. S., Siena, S., Tabernero, J., Burkes, R., Barugel, M., Humblet, Y., Bodoky, G., Cunningham, D., Jassem, J., Rivera, F., Kocákova, I., Ruff, P., Błasińska-Morawiec, M., Šmakal, M., Canon, J. L., Rother, M., Williams, R., Rong, A., Wiezorek, J., Sidhu, R., & Patterson, S. D.
- Affiliations
- Institut de Cancérologie de l'Ouest (FR)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2013-09-12
- Volume
- 369
- Issue
- 11
- Pages
- 1023-1034
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2085633477
- Cited by
- 2,263
- References
- 31
- Citations by year
- 2026: 67 · 2025: 98 · 2024: 110 · 2023: 113 · 2022: 125 · 2021: 203 · 2020: 159 · 2019: 178 · 2018: 181 · 2017: 228 · 2016: 251 · 2015: 290 · 2014: 239 · 2013: 16
- FWCI
- 142.05
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Digital Access to Libraries (submittedVersion, other-oa)
- Topics
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Health Sciences › Medicine › Oncology › Colorectal Cancer Surgical Treatments
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Keywords
- panitumumab, FOLFOX4, metastatic colorectal cancer, RAS mutations, KRAS exon 2, NRAS, BRAF mutation, anti-EGFR therapy, predictive biomarkers, progression-free survival, overall survival, oxaliplatin, 5-fluorouracil, leucovorin, treatment efficacy and safety, prognostic factors, combination chemotherapy
- MeSH terms
- Panitumumab, Antibodies, Monoclonal, Antineoplastic Combined Chemotherapy Protocols, Leucovorin, Fluorouracil, Humans, Membrane Proteins, Mutation, Neoplasm Metastasis, Organoplatinum Compounds, Proto-Oncogene Proteins, Genes, ras, Colorectal Neoplasms, Proto-Oncogene Proteins p21(ras), Disease-Free Survival, ras Proteins, GTP Phosphohydrolases, Proto-Oncogene Proteins B-raf, ErbB Receptors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.